Teo YH, Teo YN, Syn NL, et al. - The selection of the studies was carried out using PubMed, Embase, Cochrane, and SCOPUS to determine the impact of sodium‐glucose cotransporter 2 (SGLT2) inhibitors on cardiovascular and metabolic outcomes in patients without diabetes mellitus. In total, 8 randomized‐controlled trials were involved with a combined cohort of 5,233 patients. Findings revealed that there were no between‐group differences in NT‐proBNP (N‐terminal pro‐B‐type natriuretic peptide) levels, waist circumference, diastolic blood pressure, glycated hemoglobin, low‐density lipoprotein cholesterol levels, and estimated glomerular filtration rates. In patients without diabetes mellitus with heart failure, SGLT2 inhibitors improve cardiovascular outcomes. SGLT2 inhibitors demonstrated positive metabolic outcomes in weight and blood pressure control in patients without diabetes mellitus.